SUMMARY OF THE INVENTION

The present invention relates to a vaccine composition for use in a method of protecting a human subject against dengue disease, wherein said composition comprises:

(i) a dengue antigen selected from the group consisting of:
  (a) a live attenuated dengue virus;
  (b) an inactivated dengue virus;
  (c) a live attenuated or inactivated chimeric dengue virus;
  (d) a dengue virus-like particle (VLP); and
  (e) a combination of two or more of (a) to (d);

or

(ii) a nucleic acid construct or viral vector which is able to express in a human cell a dengue antigen which is a dengue VLP.

The present invention further relates to the use of a vaccine composition of the present invention for the manufacture of a medicament for protecting a human subject against dengue disease.

~~The present invention further relates to~~Also disclosed is a method of protecting a human subject against dengue disease, wherein said method comprises administering to said human subject an effective amount of a composition according to the present invention.

Additionally, the present invention relates to a kit comprising a composition according to the present invention and instructions for the use of said composition in a method of protecting a human subject against dengue disease.

Description of the Figure

Figure 1 illustrates the construction of the YF-VAX cDNA by RT-PCR and cloning

Definitions

The term "Dengue disease", as used herein, refers to the clinical symptoms exhibited by an individual following infection by any one of the four Dengue virus serotypes. Since 1970, clinical dengue has been classified according to World Health Organization guidelines as (i) dengue fever or (ii) dengue hemorrhagic fever (World

37. A composition for use according to any preceding claim, wherein said composition is lyophilized.

38. A composition for use according to any preceding claim, wherein said method comprises administering said composition to said human subject via a subcutaneous route.

39. A composition for use according to any preceding claim, wherein said composition comprises a pharmaceutically acceptably carrier or excipient.

40. ~~A method of protecting a human subject against dengue disease, wherein said method comprises administering to said human subject~~ Use of an effective amount of a composition according to any one of claims 1 to 39 in the manufacture of a medicament for protecting a human subject against dengue disease.

41. A kit comprising a composition according to any one of claims 1 to 39 and instructions for the use of said composition in a method of protecting a human subject against dengue disease.